Sun Pharma Advanced Research Company
SPARC
Sun Pharma Advanced Research Company Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | - | 1,48,071 |
| Weekly | 1.79% | 8,96,630 |
| Monthly | -7.46% | 75,45,561 |
Sun Pharma Advanced Research Company Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| SPARC | - | 1.79% | -7.46% |
| Index | - | - | - |
| Peer Avg. | 0.03% | 1.05% | 2.18% |
Sun Pharma Advanced Research Company Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| SPARC | - | -39.75 | -31.35 | -225.08 | -225.57 | - |
| Index | 35.44 | 5.98 | 16.81 | 16.99 | 18.41 | 1.19 |
| Peer Avg. | 35.31 | 3.95 | 12.55 | 16.53 | 7.42 | 2.36 |
Sun Pharma Advanced Research Company Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | -45.74% | -34.58% | - | -225.57% |
| FY '20-21 | 229.31% | 51.62% | - | -254.10% |
| FY '19-20 | -57.99% | -114.81% | -225.08% | -178.95% |
Sun Pharma Advanced Research Company Shareholding Pattern
Sun Pharma Advanced Research Company Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 137.25 | 324 | -179.90 | -203.40 |
| FY '20-21 | 252.96 | 387.93 | -129.57 | -151.14 |
| FY '19-20 | 76.81 | 386.83 | -300.25 | -312.40 |
Sun Pharma Advanced Research Company Peer Comparison
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| SPARC | 137.25 | 324 | -179.90 | -203.40 |
| IBULHSGFIN | 8,374.35 | 1,064.23 | 7,384.86 | 936.92 |
| NETWORK18 | 3,023.76 | 2,483.58 | 571.62 | 373.79 |
Sun Pharma Advanced Research Company Share Price
Sun Pharma Advanced Research Company Limited is an Indian clinical stage biopharmaceutical company. The company is engaged in R&D (RandD) of pharmaceutical products for unmet medical needs in the fields of oncology, neurodegeneration and immunology. The company develops new chemical entities (NCEs), new biological entities and reformulated products. Its NICE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its new drug delivery systems (NDDS) include Wrap Matrix technology, Lipexelle technology and TearAct technology. Wrap Matrix technology is useful in the development of controlled release tablets. It developed Elepsia XR using Wrap MatrixTM technology. Lipexelle technology for ophthalmic formulations. The company also developed Xelpros, a BAK-free latanoprost eye drop developed with Lipexelle technology. Xelpros is marketed by its partner in the United States. He also developed PDP-716 eye drops based on TearAct technology for the treatment of glaucoma.